ArticleFrontiers in oncology2026
Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neuroretinitis is a very rare but recognized immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. We present a case of likely ICI-associated neuroretinitis following combination nivolumab and ipilimumab treatment for stage IIIC cutaneous melanoma. Observations: Our patient is a 48-year-old woman with stage IIIC melanoma who developed acute left eye vision loss approximately three months after initiating nivolumab and ipilimumab, near the end of a corticosteroid taper for a concurrent systemic irAE. Examination showed best-corrected visual acuity of 20/400, severely reduced color vision (2/14 Ishihara plates), and a relative afferent pupillary defect in the left eye. Initial fundus exam of that eye revealed optic disc edema with nasal hemorrhages as well as peripapillary macular edema. There was a central scotoma with nasal steps on the Humphrey visual field (mean deviation -13.24 dB). Fluorescein angiography demonstrated disc leakage with inferior arcuate hypoperfusion. Optical coherence tomography (OCT) showed subsequent intraretinal exudates in the nasal macula bilaterally, worse in the left eye. Infectious workup and neuro-imaging were unremarkable. The patient was treated with intravenous methylprednisolone (IVMP) pulse and intravenous immunoglobulin (IVIG) at initial hospitalization, followed by a slow oral prednisone taper along with monthly IVIG outpatient. Her visual acuity in the left eye improved to 20/20 at 6-month follow-up visit. Conclusions and importance: ICI-associated neuroretinitis is rare but vision-threatening and may emerge or worsen during systemic corticosteroid tapering for concurrent irAEs. Prompt recognition, exclusion of infectious mimics, and multidisciplinary management can yield meaningful visual recovery. Comprehensive neuro-ophthalmic assessment for ICI-associated neuro-ophthalmic complications including evaluation of color vision and pupillary function, documentation of fundus appearance, and additional ancillary testing with visual field and OCT analysis is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.